Allogeneic CAR T Company Prepares to Widen Access to Patients

An allogeneic CAR T-cell therapy company is planning a pivotal Phase III randomized-control trial, hoping their products can reach more patients and help those who can’t access autologous therapies.

The post Allogeneic CAR T Company Prepares to Widen Access to Patients appeared first on GEN - Genetic Engineering and Biotechnology News.